A 52-Year-Old Woman With HER2-Positive Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
A 52-Year-Old Woman With HER2-Positive Breast Cancer | Targeted …
May 22, 2019
targetedonc.com
The Targeted Pulse: IL-21 Promises to Revolutionize Treatment for Glioblastoma, Pembrolizumab Trials Halted in Lung and Skin Cancer, and More | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Targeted Pulse: IL-21 Promises to Revolutionize Treatment for Gli…
Sep 8, 2024
targetedonc.com
Case 3: Essential Thrombocythemia (ET) | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Case 3: Essential Thrombocythemia (ET) | Targeted Oncology - Immun…
May 27, 2021
targetedonc.com
Current Treatment Options for DLBCL Besides R-CHOP Chemotherapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Current Treatment Options for DLBCL Besides R-CHOP Chemoth…
Mar 16, 2020
targetedonc.com
Mechanism of Action: Abraxane | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mechanism of Action: Abraxane | Targeted Oncology - Immunothera…
Feb 5, 2014
targetedonc.com
Understanding Treatment Options in Nasopharyngeal Carcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1:50
Understanding Treatment Options in Nasopharyngeal Carcinoma | Targ…
8 months ago
targetedonc.com
AML: Toxicities With CPX-351 | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
AML: Toxicities With CPX-351 | Targeted Oncology - Immunothera…
Jul 9, 2018
targetedonc.com
Initial Treatment Options for mCRPC | Targeted Oncology - Immunother…
Nov 10, 2021
targetedonc.com
EMERALD subgroup analysis: Elacestrant in endocrine-sensitiv…
11 months ago
targetedonc.com
Addressing Unmet Needs in Renal Cell Carcinoma | Targeted Oncolo…
Apr 5, 2022
targetedonc.com
NCCN Guidelines for Castleman's Disease | Targeted Oncology - Im…
Oct 31, 2016
targetedonc.com
Multiple Myeloma Treatment: New Therapies vs Stem Cell Transplan…
Apr 3, 2024
targetedonc.com
Introduction & Case 1 Presentation: mHSPC | Targeted Oncology - Im…
11 months ago
targetedonc.com
Standard of Care for PSMA-Positive mCRPC | Targeted Oncology - Im…
Jun 30, 2021
targetedonc.com
Discussing the Investigation of Polatuzumab Combination Therap…
Oct 24, 2023
targetedonc.com
DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoi…
7 months ago
targetedonc.com
Options for MRD Testing Affect Patient Treatment Plan in Lung Ca…
10 months ago
targetedonc.com
ASH 2024 Preview for Community Oncologists: The Show and After …
11 months ago
targetedonc.com
The Differences Between mCRPC and nmCRPC | Targeted Oncolog…
Jul 17, 2019
targetedonc.com
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
Nov 14, 2023
targetedonc.com
FDA's July 2024 Roundup: Breakthroughs and Milestones in …
Aug 2, 2024
targetedonc.com
Case 3: Disease Progression and Transformation in ET | Targeted O…
May 27, 2021
targetedonc.com
Case Presentation: 63-Year-Old Man With Advanced HCC | Targeted On…
Sep 9, 2019
targetedonc.com
When to Choose Chemotherapy vs CDK4/6 Inhibitors | Targeted Onco…
Apr 29, 2019
targetedonc.com
Selecting an Appropriate Second-Line Treatment for Metastatic End…
Jan 19, 2023
targetedonc.com
CARD Trial: How Does CSPC Progress to CRPC? | Targeted On…
1 month ago
targetedonc.com
Case 3: A Patient With Metastatic HCC | Targeted Oncology - Immun…
Jan 3, 2022
targetedonc.com
Understanding GOG-0218 & ICON7 Trials | Targeted Oncology - Immu…
Apr 15, 2020
targetedonc.com
Treating Squamous vs Nonsquamous Disease | Targeted …
Nov 15, 2013
targetedonc.com
Overview: A 70-Year-Old Woman With Advanced Endometrial Canc…
Mar 1, 2022
targetedonc.com
See more videos
Static thumbnail place holder